92 related articles for article (PubMed ID: 22929802)
21. Prognostic significance of DNA di-tetraploidy in neuroblastoma.
Ladenstein R; Ambros IM; Pötschger U; Amann G; Urban C; Fink FM; Schmitt K; Jones R; Slociak M; Schilling F; Ritter J; Berthold F; Gadner H; Ambros PF
Med Pediatr Oncol; 2001 Jan; 36(1):83-92. PubMed ID: 11464912
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma.
Hou P; Ji M; Yang B; Chen Z; Qiu J; Shi X; Lu Z
Cancer; 2006 Apr; 106(7):1602-9. PubMed ID: 16502411
[TBL] [Abstract][Full Text] [Related]
23. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma.
Shohet JM; Hicks MJ; Plon SE; Burlingame SM; Stuart S; Chen SY; Brenner MK; Nuchtern JG
Cancer Res; 2002 Feb; 62(4):1123-8. PubMed ID: 11861392
[TBL] [Abstract][Full Text] [Related]
24. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
[TBL] [Abstract][Full Text] [Related]
25. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.
Ackermann S; Kocak H; Hero B; Ehemann V; Kahlert Y; Oberthuer A; Roels F; Theißen J; Odenthal M; Berthold F; Fischer M
BMC Cancer; 2014 Nov; 14():840. PubMed ID: 25406647
[TBL] [Abstract][Full Text] [Related]
26. [Hypermethylation as a potential prognostic factor and a clue to a better understanding of the molecular pathogenesis of medulloblastoma--results of a genomewide methylation scan].
Frühwald MC; O'Dorisio MS; Smith L; Dai Z; Wright FA; Paulus W; Jürgens H; Plass C
Klin Padiatr; 2001; 213(4):197-203. PubMed ID: 11528554
[TBL] [Abstract][Full Text] [Related]
27. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
29. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
[TBL] [Abstract][Full Text] [Related]
30. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
[TBL] [Abstract][Full Text] [Related]
31. The correlation analysis of WWOX expression and cancer related genes in neuroblastoma- a real time RT-PCR study.
Nowakowska M; Płuciennik E; Wujcicka WI; Sitkiewicz A; Kazanowska B; Zielińska E; Bednarek AK
Acta Biochim Pol; 2014; 61(1):91-7. PubMed ID: 24455756
[TBL] [Abstract][Full Text] [Related]
32. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.
Ashton LJ; Murray JE; Haber M; Marshall GM; Ashley DM; Norris MD
Pharmacogenet Genomics; 2007 Sep; 17(9):709-17. PubMed ID: 17700360
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.
Gómez S; Castellano G; Mayol G; Suñol M; Queiros A; Bibikova M; Nazor KL; Loring JF; Lemos I; Rodríguez E; de Torres C; Mora J; Martín-Subero JI; Lavarino C
Epigenomics; 2015 Oct; 7(7):1137-53. PubMed ID: 26067621
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.
Decock A; Ongenaert M; Hoebeeck J; De Preter K; Van Peer G; Van Criekinge W; Ladenstein R; Schulte JH; Noguera R; Stallings RL; Van Damme A; Laureys G; Vermeulen J; Van Maerken T; Speleman F; Vandesompele J
Genome Biol; 2012 Oct; 13(10):R95. PubMed ID: 23034519
[TBL] [Abstract][Full Text] [Related]
36. Aberrant methylation of multiple genes in neuroblastic tumours. relationship with MYCN amplification and allelic status at 1p.
Gonzalez-Gomez P; Bello MJ; Lomas J; Arjona D; Alonso ME; Amiñoso C; Lopez-Marin I; Anselmo NP; Sarasa JL; Gutierrez M; Casartelli C; Rey JA
Eur J Cancer; 2003 Jul; 39(10):1478-85. PubMed ID: 12826052
[TBL] [Abstract][Full Text] [Related]
37. RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.
Misawa A; Tanaka S; Yagyu S; Tsuchiya K; Iehara T; Sugimoto T; Hosoi H
Br J Cancer; 2009 Jan; 100(2):399-404. PubMed ID: 19165202
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation.
Parodi F; Carosio R; Ragusa M; Di Pietro C; Maugeri M; Barbagallo D; Sallustio F; Allemanni G; Pistillo MP; Casciano I; Forlani A; Schena FP; Purrello M; Romani M; Banelli B
Biochim Biophys Acta; 2016 Dec; 1859(12):1502-1514. PubMed ID: 27751904
[TBL] [Abstract][Full Text] [Related]
39. Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
Banelli B; Bonassi S; Casciano I; Mazzocco K; Di Vinci A; Scaruffi P; Brigati C; Allemanni G; Borzì L; Tonini GP; Romani M
Int J Cancer; 2010 Feb; 126(3):656-68. PubMed ID: 19626586
[TBL] [Abstract][Full Text] [Related]
40. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X
Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
